FC
GILD icon

Fore Capital’s Gilead Sciences GILD Stock Holding History

Fore Capital’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-70,000
Closed -$4.82M – 61
2021
Q2 		$4.82M Buy
+70,000
New +$4.67M 1.47% 12
2021
Q1 		– Sell
-70,000
Closed -$4.08M – 77
2020
Q4 		$4.08M Buy
+70,000
New +$4.22M 1% 12

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Fore Capital's GILD Position: Q3 2021 in Review

Fore Capital sold out of Gilead Sciences (GILD) in Q3 2021, closing a stake of 10,000 shares — an estimated $689K sold.

Fore Capital first reported a position in GILD in Q4 2020 and held it in 2 quarters. The position peaked at $689K in Q2 2021. 1,564 funds tracked by Wall St. Rank hold GILD as of Q3 2021.

  • Fore Capital reported no remaining Gilead Sciences position as of Q3 2021 after selling out during the quarter.
  • Fore Capital sold 10,000 Gilead Sciences shares in Q3 2021, an estimated $689K.
  • Fore Capital first reported a position in Gilead Sciences in Q4 2020 and held it in 2 quarters.
  • Fore Capital's Gilead Sciences position peaked at $689K in Q2 2021.
  • 1,564 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2021.

Based on Fore Capital's 13F filing for Q3 2021, filed 12 Nov 2021.